Biophan's Next-Generation Technology to Be Showcased at International Transcatheter Cardiovascular Conference; Solutions to Enable MRI Visualization and Safety on Display at Cardiovascular Research Foundation Symposium
"The TCT symposium draws the attendance of physicians from all over the world, providing a valuable opportunity for Biophan to present its technologies to the international cardiovascular community," said Michael Weiner, Biophan CEO. "Biophan will benefit not only from this global audience, but also by showcasing our technology, which continues to define the cutting-edge of innovation in our fields of specialization. "Biophan is committed to introducing novel biomedical solutions to major healthcare markets via strategic joint ventures and licensing agreements with medical device manufacturing companies. Biophan creates solutions to enable safety and image compatibility for the $12 billion of medical devices with limitations in Magnetic Resonance Imaging (MRI).
“Biophan will benefit not only from this global audience, but also by showcasing our technology, which continues to define the cutting-edge of innovation in our fields of specialization.”
Biophan officers John Lanzafame, Vice President, Business Development; Jeffrey L. Helfer, Vice President of Engineering, Dr. Michael Friebe, Biophan-Europe President and CEO, and Dr. Andreas Melzer, Biophan-Europe Chief Technology Officer, will introduce a range of Company innovations developed at Biophan's headquarters in the United States and at its Biophan-Europe division in Germany.
Biophan is a biomedical development leader with a powerful intellectual property portfolio of 156 U.S. patents, licenses, or applications and 46 international applications. The Company recently launched an initiative to expand its presence in cardiovascular diagnostic and therapeutic devices, one of the fastest-growing segments of the biomedical industry, with an expected value of nearly $28 billion before the end of this decade.
About Transcatheter Cardiovascular Therapeutics
Transcatheter Cardiovascular Therapeutics (TCT), sponsored by the Cardiovascular Research Foundation, is a scientifically stimulating symposium for physicians and other healthcare professionals who specialize in the field of interventional vascular therapy. Building upon the success of previous TCTs, live cases will continue to be the core of the TCT conference experience. More than 60 hours of live cases originating in 27 US and international centers are planned, and will be presented simultaneously in 4 separate venues. Additional highlights of TCT 2005 include late-breaking trials, more than 600 original oral and poster abstract presentations, 9 scientific symposia, and much more. As always, TCT will stress evidence-based medicine, with an emphasis on clinical trials and controlled registry data to guide clinical patient care, and which are likely to impact future practice patterns. For more information visit http://tct2005.com/.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 42 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol "BTN." For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.